新型口服抗凝药联合阿司匹林治疗非瓣膜性房颤的临床分析

Abstract
Figure/Table
References (15)
Related Citation (14)

Download: PDF (0 KB) HTML (28 KB)
Export: BibTeX | EndNote (RIS)

Abstract ObjectiveTo investigate the clinical effect of new oral anticoagulant(Dabigatran)combined with Aspirin in the treatment of nonvalvular atrial fibrillation.Methods One hundred and fifty cases of nonvalvular atrial fibrillation treated in our hospital from February 2014 to August 2016 were selected as the subjects.According to the random number table method,they were divided into control group,research group 1 and research group 2,50 cases in each group.The controlgroupwastreated with Warfarin,and the research group 1 was treated with Dabigatran,and the research group 2 was treated with Aspirin Tablets combined with Dabigatran.The changes of coagulation index and cerebral hemorrhage,upper gastrointestinal bleeding,transient ischemic attack,pulmonary embolism,cerebral embolism and death were compared in the three groups before and after treatment.Results Before treatment,there was no significant difference in coagulation index between the three groups(P＞0.05).After treatment,the coagulation indexes in the three groups were significantly higher than those before treatment,and the differences were statistically significant(P＜0.05),while there was no significant difference in coagulation index in the three groups after treament(P＞0.05).No pulmonary embolism and death were found in all three groups.The incidence of transient ischemic attack,cerebral embolism,cerebral hemorrhage and upper gastrointestinal bleeding of research group 1 and research group 2 were both lower than those in the control group,and the differences were statistically significant(P＜0.05).The incidence of hemorrhage and upper gastrointestinal bleeding of research group 1 were lower than those in the research group 2,and the differences were statistically significant(P＜0.05).Conclusion In the treatment of nonvalvular atrial fibrillation,Dabigatran combined with Aspirin Tablets has no significant improvement in efficacy compared with Dabigatran alone,but increases the risk of bleeding.Compared with warfarin alone,combination therapy can reduce the incidence of transient ischemic attack,cerebral embolism and other events.

Key words： Nonvalvular atrial fibrillation Dabigatran Aspirin Warfarin

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	HUANG Han-hui
	HUANG Kai

Cite this article:

HUANG Han-hui,HUANG Kai. Clinical analysis of a new oral anticoagulant drug combined with Aspirin in the treatment of nonvalvular atrial fibrillation[J]. 中国当代医药, 2018, 25(7): 51-53.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2018/V25/I7/51

[1]	王汝朋，杨水祥.利伐沙班和达比加群酯及华法林在非瓣膜性心房颤动患者抗凝治疗的研究[J].中华老年心脑血管病杂志，2015，17（12）：1246-1249.
[2]	张玉静，李学文.达比加群酯在非瓣膜性心房颤动抗凝治疗中抗凝监测指标的研究[J].中华心律失常学杂志，2016，20（3）：220-223.
[3]	张清琼，孙学春，周晓芳，等.新型口服抗凝药物治疗高龄非瓣膜性房颤患者的疗效分析[J].重庆医学，2016，45（4）：486-489.
[4]	姚璐，张薇，田国祥，等.达比加群酯应用于高龄老年非瓣膜性心房纤颤患者中的安全性评价[J].中国循证心血管医学杂志，2016，8（5）：547-549.
[5]	马国力，毕亚艳，佟春芝，等.达比加群酯在非瓣膜性心房颤动抗凝治疗中的作用机制及其他抗凝机制[J].医学研究杂志，2016，45（4）：165-167.
[6]	郑炜平，陈锋，李永坤，等.达比加群酯对非瓣膜性房颤导管消融围术期抗凝疗效和安全性的Meta分析[J].实用心电学杂志，2016，25（5）：334-341.
[7]	王晶锐，胡硕强，张银，等.达比加群酯对非瓣膜性房颤合并脑卒中患者凝血功能的影响[J].医学临床研究，2016，33（6）：1141-1143.
[8]	胡高频，孙飞，姜东炬.达比加群酯治疗高龄女性非瓣膜性心房纤颤的安全性和有效性分析[J].临床军医杂志，2016，44（9）：953-955.
[9]	卢奕，温连安，李东，等.非瓣膜性房颤达比加群酯抗凝治疗的疗效及安全性评价[J].中国药业，2017，26（6）：49-51.
[10]	陈岚，徐进，任骞，等.非瓣膜性房颤患者经皮冠脉介入术后达比加群酯加双联抗血小板抗栓疗效观察[J].陕西医学杂志，2016，45（6）：758-759.
[11]	金鹏，周琪，石向明，等.利伐沙班和达比加群酯治疗高龄非瓣膜性房颤病人的安全性及疗效观察[J].中西医结合心脑血管病杂志，2016，14（13）：1504-1506.
[12]	姚璐，张薇，武云涛，等.达比加群酯对高龄非瓣膜性心房颤动患者凝血功能的影响[J].临床误诊误治，2016，29（6）：33-35.
[13]	陈月，赵京玉，鲁宛灵，等.达比加群酯与华法林对非瓣膜性心房颤动患者抗凝效果及安全性的系统评价[J].中国临床药理学杂志，2016，32（21）：2008-2011.
[14]	梁羡方，赵新军，谢绍洽，等.达比加群酯联合阿司匹林片治疗非瓣膜性房颤患者的疗效和安全性[J].心脏杂志，2015，27（5）：560-564.
[15]	韩文杰，刘恒亮.达比加群酯联合阿司匹林治疗非瓣膜性房颤效果分析[J].疾病监测与控制，2017，11（1）：59-60.